Drugs Made In America Acquisition DMII
NASDAQ DMII
$10.14 +0.00 (+0.00%)
As of: Aug 21, 2026 · 2:38 PM EDT

Drugs Made In America Acquisition (DMII) Operating Income (2025)

Drugs Made In America Acquisition (DMII) posted quarterly Operating Income of -$235472.0 for Q4 2025, down 51.42% quarter-over-quarter from -$155513.0 in Q3 2025.

Drugs Made In America Acquisition (DMII) Operating Income (2025) Analysis & Trends

Drugs Made In America Acquisition (DMII) has reported Operating Income for 1 consecutive years, with -$235472.0 the latest figure, recorded in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Oxley Bridge Acquisition 585.76 Mn 585.76 Mn - -162,277.00
2 Launch Two Acquisition 557.86 Mn 557.86 Mn - -194,528.00
3 Drugs Made In America Acquisition 507.00 Mn 507.00 Mn - -112,227.00
4 Cantor Equity Partners IV 468.00 Mn 468.00 Mn - -174,182.00
5 GP-Act III Acquisition 401.06 Mn 401.06 Mn - -1.47 Mn
6 Aldel Financial 397.49 Mn 397.49 Mn - -115,742.00
7 Republic Digital Acquisition 389.25 Mn 388.51 Mn - -96,300.00
8 Gores Holdings X 385.06 Mn 384.87 Mn - -1.35 Mn
9 Agriculture & Natural Solutions Acquisition 377.29 Mn 377.04 Mn - -
10 CSLM Digital Asset Acquisition Corp III 322.52 Mn 314.90 Mn - -623,674.00

Historic Data

Download Data
DateValue
Dec 31, 2025 -235,472.00
Sep 30, 2025 -155,513.00